270 related articles for article (PubMed ID: 24417077)
1. [Advances in the research of anti-CD20 therapeutic monoclonal antibodies].
Deng CL; Zou J; Song HF
Yao Xue Xue Bao; 2013 Oct; 48(10):1515-20. PubMed ID: 24417077
[TBL] [Abstract][Full Text] [Related]
2. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
4. The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
Evers M; Jak M; Leusen JHW
Expert Opin Biol Ther; 2018 Sep; 18(9):973-982. PubMed ID: 30084674
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
Engelhard M
Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
[TBL] [Abstract][Full Text] [Related]
6. What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
Chaudhry M; Cheson BD
Expert Rev Hematol; 2015 Dec; 8(6):733-42. PubMed ID: 26368831
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y
Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
9. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
10. Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.
Reagan PM; Friedberg JW
Oncology (Williston Park); 2017 May; 31(5):402-11. PubMed ID: 28516439
[TBL] [Abstract][Full Text] [Related]
11. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
12. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
Pers YM; Jorgensen C
Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
[TBL] [Abstract][Full Text] [Related]
13. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
Tobinai K; Klein C; Oya N; Fingerle-Rowson G
Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
[TBL] [Abstract][Full Text] [Related]
14. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
15. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
16. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.
Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S
Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686
[TBL] [Abstract][Full Text] [Related]
17. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
18. Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art.
Witkowska M; Smolewski P
Curr Drug Targets; 2016; 17(9):1072-82. PubMed ID: 26343115
[TBL] [Abstract][Full Text] [Related]
19. Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
Leonard JP
Clin Adv Hematol Oncol; 2012 Aug; 10(8):540-2. PubMed ID: 23073054
[No Abstract] [Full Text] [Related]
20. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.
Taylor RP; Lindorfer MA
Curr Opin Immunol; 2008 Aug; 20(4):444-9. PubMed ID: 18585457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]